BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript

BioCardia, Inc. (NASDAQ:BCDA) Q2 2025 Earnings Conference Call August 11, 2025 7:00 AM ET

Company Participants

David McClung – Chief Financial Officer
Miranda Peto Benvenuti – Corporate Participant
Peter A. Altman – CEO, President & Director

Conference Call Participants

James Francis Molloy – Alliance Global Partners, Research Division
Kumaraguru Raja – Brookline Capital Markets, LLC, Research Division
Lander Egaña-Gorroño – H.C. Wainwright & Co, LLC, Research Division

Operator

Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the BioCardia Second Quarter Financial Results and Business Update Conference call. [Operator Instructions] Participants of this call are advised that the audio of this conference call is being broadcast live over the Internet and is also being recorded for playback purposes. A webcast replay of the call will be available approximately 1 hour after the end of the call.

I would now like to turn the call over to Miranda Peto of BioCardia Investor Relations. Please go ahead, Miranda.

Miranda Peto Benvenuti

Thank you very much. Good afternoon, and thank you all for participating in today’s conference call. Joining me from BioCardia’s leadership team are Peter Altman, President and Chief Executive Officer; and David McClung, the company’s Chief Financial Officer.

During this call, management will be making forward-looking statements including statements that address BioCardia’s expectations for future performance and operational results, references to management’s intentions, beliefs, projections, outlook, analyses and current expectations. These factors include, among others, the inherent uncertainties associated with developing new products technologies and obtaining regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the Risk Factors and cautionary statements described in BioCardia’s report on Form 10-K filed with the SEC on March 26, 2025, and in subsequently filed reports on Form 10-Q.